241 (PB021) - Development of a novel antibody-drug conjugate targeting both CEACAM5 and CEACAM6

Autor: Arias, K., Enos, C., Spear, M., Austin, D., Almofeez, R., Kortchak, S., Pincus, L., Kwon, Y., Gelber, C.

Publikováno v: In European Journal of Cancer October 2022 174 Supplement 1:S87-S87

CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells.

Autor: Cardenas KCA; Stromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA., Enos CW; Eastern Virginia Medical School, Norfolk, Virginia, USA., Spear MR; Stromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA., Austin DE; Stromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA., Almofeez R; Stromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA., Kortchak S; Stromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA., Pincus L; Stromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA., Guo HB; University of Georgia Cancer Center, Department of Biochemistry and Molecular Biology and the Complex Carbohydrate Research Center (CCRC), USA., Dolezal S; University of Georgia Cancer Center, Department of Biochemistry and Molecular Biology and the Complex Carbohydrate Research Center (CCRC), USA., Pierce JM; University of Georgia Cancer Center, Department of Biochemistry and Molecular Biology and the Complex Carbohydrate Research Center (CCRC), USA., Furth E; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA., Gineste C; Vaxxinity Inc, Merritt Island, Fl, USA., Kwon Y; Institute: Food and Drug Administration, CDER, MD, USA., Gelber C; Stromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA.

Publikováno v: Current cancer drug targets [Curr Cancer Drug Targets] 2024; Vol. 24 (7), pp. 720-732.